



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/576,428	08/31/2006	Martin S. Zand	17661692	2423
26774 7590 03/09/2010 NIXON PEABODY LLP - PATENT GROUP 1100 CLINTON SQUARE ROCHESTER, NY 14604				
EXAMINER SCHWADRON, RONALD B				
ART UNIT		PAPER NUMBER		
1644				
MAIL DATE		DELIVERY MODE		
03/09/2010		PAPER		

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.



## UNITED STATES DEPARTMENT OF COMMERCE

## U.S. Patent and Trademark Office

Address : COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10576428	8/31/2006	ZAND ET AL.	17661692

NIXON PEABODY LLP - PATENT GROUP  
1100 CLINTON SQUARE  
ROCHESTER, NY 14604

## EXAMINER

Ron Schwadron, Ph.D.

ART UNIT	PAPER
----------	-------

1644

20100304

DATE MAILED:

**Please find below and/or attached an Office communication concerning this application or proceeding.**

## Commissioner for Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

**Page 17 contains amino acid sequences (z-DEVD-fmk, z-IETD-fmk and z-LEHD-fmk) for which no sequence listing has been submitted. A search of the aforementioned terms on GOOGLE reveals that the aforementioned terms recite tetramer polypeptides (aka DEVD or IETD or LEHD).**

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Ron Schwadron, Ph.D.  
Primary Examiner, Art Unit 1644

/Ron Schwadron/  
Primary Examiner, Art Unit 1644